^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)

    i
    Other names: RG6264, RG 6264, RO7198574, Perjeta/Herceptin, RG-6264, RO-7198574, RO 7198574
    Company:
    Halozyme, Roche
    Drug class:
    HER2 inhibitor, HER2 dimerization inhibitor
    Related drugs:
    6d
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2026 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    14d
    PHERGAIN-2: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (clinicaltrials.gov)
    P2, N=393, Active, not recruiting, MedSIR | Trial primary completion date: Sep 2025 --> Mar 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    tamoxifen • Kadcyla (ado-trastuzumab emtansine) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    22d
    ProHer: A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=346, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    1m
    Prospective, multicenter study of neoadjuvant Phesgo with chemotherapy de-escalation for HER2-positive FUSCC HER2-CLA early breast cancer (ChiCTR2500109333)
    P4, N=31, Not yet recruiting, The affiliated hospital of southwest medical university; The affiliated hospital of southwest medical university
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    1m
    An exploratory study of neoadjuvant therapy with toripalimab combined with Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection and nab-paclitaxel in patients with HER2-positive stage II–III breast cancer. (ChiCTR2500108585)
    P2, N=112, Recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine) • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    1m
    A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (clinicaltrials.gov)
    P3, N=922, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • EGFR positive
    |
    paclitaxel • docetaxel • tamoxifen • giredestrant (RG6171) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    2ms
    HER2CLIMB-05: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial primary completion date: Feb 2026 --> Sep 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive
    |
    Perjeta (pertuzumab) • Tukysa (tucatinib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    3ms
    Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2positive breast cancer with high HER2 addiction and a complete response following standard anti- HER2-based neoadjuvant therapy (ELPIS trial) Omisión de cirugía y disección de ganglios linfáticos centinela en cáncer de mama HER2 positivo de bajo riesgo clínico con tumor de alta adicción a HER2 y una respuesta completa después de la terapia neoadyuvante basada en anti-HER2 estándar (ensayo ELPIS) (clinicaltrialsregister.eu)
    P2, N=27, Ongoing, Fundació Clínic per a la Recerca Biomèdica
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    paclitaxel • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    3ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Phase classification: P1 --> P1/2
    Enrollment closed • Phase classification
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • perzebertinib (RG6596)
    3ms
    OPTIMAL-BC: Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer (clinicaltrials.gov)
    P=N/A, N=112, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Liporaxel (paclitaxel oral)